In the news
New large-scale prostate cancer genome project
Source: GenomeWeb news
The International Cancer Genome Consortium (ICGC) has announced the launch of a new initiative to study the genetics of prostate cancer, which should lead to new ways to diagnose and treat the disease.
There are currently 37 research projects funded by ICGC worldwide. The goal of the latest project, the Canada Prostate Cancer Genome Network (or CPC Gene), is to identify mutations in the genes involved in prostate cancer. It is hoped that this will lead to better diagnosis of tumours, improved assessment of tumour aggressiveness (and therefore more appropriate treatment choices), as well as the development of novel cancer drugs. CPC Gene will be led by scientists at the Ontario Cancer Institute, and will include teams from several other Canadian research institutions. Another ICGC project announced earlier this year and based in Germany will investigate the genetics of early prostate cancer in the search for diagnostic markers (see HealthCanal report).
Prostate cancer is the most common form of cancer in men, affecting primarily those over the age of 50, and a small but significant proportion of these cases may be a hereditary form of the disease. In all cases, a better understanding of the underlying genetic changes will aid early detection and clinical management.